Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J eyes contact lens solution market

This article was originally published in The Gray Sheet

Executive Summary

The aftermath of an outbreak of eye infections linked to contact lens care solutions made by Bausch & Lomb provides a "significant" opportunity for Johnson & Johnson/Vistakon to move into the solution arena, Dan Casey, group chairman of the eye products unit says Sept. 6. The recent Fusarium keratitis infections, which resulted in a worldwide recall of B&L's ReNu with MoistureLoc solution, open the door to "bring real innovation to the category," according to Casey. Vistakon is looking at acquisitions and licensing that would allow the firm to participate in the solutions market (1"The Gray Sheet" May 22, 2006, p. 17). J&J's pending acquisition of Pfizer's consumer products business will complement J&J's Acuvue contact lens line by adding Pfizer's Visine eye drops...

You may also be interested in...



B&L’s MoistureLoc Worldwide Recall: Firm Ties Formulation To Infection

With evidence pointing to the basic formulation of Bausch & Lomb's ReNu with MoistureLoc contact lens solution as a contributing factor in an outbreak of serious eye infections, the company bit the bullet May 15 and issued a permanent, worldwide recall of the lucrative product

Minute Insight: Medtronic Brings Hugo RAS To Canada

Health Canada has licensed Hugo for urologic and gynecologic laparoscopic surgical procedures.

Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go

Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.

UsernamePublicRestriction

Register

MT023973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel